Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2004

View Archived Issues

License termination agreement returns LEP and LED rights to NeoPharm

BioMimic formed to develop human applications of Receptor Mimic Technology

Novel DNA cancer vaccine enters phase I trial

Enrollment completed in phase I dose escalation study of DB-289 for malaria

EMZ-702 enters clinical development for hepatitis C

Final results of Sanofi-Aventis' offer for Aventis

IDEA-033 enters phase III study for peripheral pain

Novel L-DOPA prodrugs designed by Yissum researchers

New antitumor agents prepared and tested at Dr. Reddy's

New p38 MAP kinase inhibitors emerge from Pfizer R&D

CV Therapeutics presents new adenosine A1 agonists and their use as antiarrhythmic agents

New fatty acid oxidation inhibitors in early development at CV Therapeutics

Pfizer presents new TGF-beta type II receptor kinase inhibitors

BMS scientists identify new calcium-sensing receptor antagonists

New antitumor pregnene derivative isolated from gorgonian species

Complete response for Symlin submitted to FDA

Proquin XR NDA accepted by FDA

Isis licenses second antisense anticancer drug candidate to Lilly

FDA accepts sBLA for expanded use of Bexxar

Positive preliminary phase III results with M6G in postoperative pain

New diagnostic test for early detection of invasive fungal infections

New phase I data on the safety profile of cantuzumab mertansine in advanced cancer

Clinical evidence confirms the positive effects of etanercept in psoriasis and rheumatoid arthritis

Rasagiline improves motor symptoms and tremor in PD

Tacrolimus and ciclosporin equally affect glucose metabolism after pancreas transplantation

Statins reported to improve survival of patients with advanced heart failure

Theophylline improves the efficacy of standard therapy for asthma attacks

Marketing approval for Hexvix

European marketing authorization submitted for once-monthly oral formulation of Bonviva

Approvable letter for Extravan for glaucoma

Expanded indication for Eloxatin for early stage colon cancer treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...